Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2003

View Archived Issues

Gemin X claims novel compounds for cancer, viral infections and autoimmune diseases

Novel antitumor ecteinascidins reported by Spanish research team

CV Therapeutics describes novel fatty acid oxidation inhibitors

New prostanoid EP4 receptor agonists and their use in osteoporosis

Bayer claims new series of thiazole-based anti-HSV agents

Novel antibacterial dimeric vancomycin derivatives claimed by Theravance

New MMP inhibitors for arthritis and other disorders discovered at Leo

Novel neuraminidase inhibitors in early development at BioCryst

Two series of PDE4 inhibitors identified by Merck researchers

Active Biotech reports on recent progress

Potential use of DX-88 in the treatment of hereditary angioedema

Good safety and efficacy for INS-37217 in the treatment of perennial allergic rhinitis

Improved management of malignant liver tumors with ferucarbotran-enhanced MRI

Sonazoid-enhanced ultrasound reported to improve the detection of liver metastases

Mepolizumab reported to inhibit eosinophil function in asthma and allergy

Antiallergic effects of CAT-213 in grass pollen-sensitive subjects

Telik offers progress report

NicOx reviews phase II data for AZD-3582

Velcade NDA granted priority review

Endovasc plans to file Liprostin IND for diabetic neuropathy

Viragen's natural interferon alfa approved in South Africa

Phase II results announced for ISA-247 in psoriasis

Enrollment completed in phase III trial of Aptosyn/Taxotere in NSCLC

Gilead's Hepsera approved for marketing in E.U. countries

Nippon Kayaku to seek marketing clearance for gusperimus in Europe

SMP-114 now in phase II development in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...